Key Points aTyr Pharma's leading candidate is targeting a relatively large market with unmet needs. The biotech company is expected to release data from a phase 3 clinical trial soon. Though things look somewhat promising for the company, aTyr Pharma is a risky stock. 10 stocks we like better than aTyr Pharma › Some prominent biotech companies tend to capture the majority of investors' and analysts' attention compared to their industry peers. aTyr Pharma (NASDAQ: LIFE), a small-cap, clinical-stag ...